The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride
Open accessAbstract
Background: Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) leads to multiple metabolic changes, reduction in glucose levels and body weight are well established. In people with type 2 diabetes, GLP-1 RAs reduce the risk of cardiovascular (CV) disease and may also potentially represent a treatment for fatty liver disease. The mechanisms behind these effects are still not fully elucidated. The aim of the study was to investigate whether treatment with liraglutide is associated with favourable metabolic changes in cases of both CV disease and fatty liver disease. Methods: In a prespecified post-hoc analysis of a double-blind, placebo-controlled trial in 62 individuals with type 2 diabetes (GLP-1 RA liraglutide or glimepiride, both in combination with metformin), we evaluated the changes in plasma molecular lipids and polar metabolites after 18 weeks of treatment. The lipids and polar metabolites were measured by using ultra-high-performance liquid chromatography quadrupole time-of-flight mass spectrometry (UHPLC-QTOFMS). Results: In total, 340 lipids and other metabolites were identified, covering 14 lipid classes, bile acids, free fatty acids, amino acids and other polar metabolites. We observed more significant changes in the metabolome following liraglutide treatment compared to with glimepiride, particularly as regards decreased levels of cholesterol esters hexocyl-ceramides, lysophosphatidylcholines, sphingolipids and phosphatidylcholines with alkyl ether structure. In the liraglutide-treated group, lipids were reduced by approximately 15% from baseline, compared to a 10% decrease in the glimepiride group. At the pathway level, the liraglutide treatment was associated with lipid, bile acid as well as glucose metabolism, while glimepiride treatment was associated with tryptophan metabolism, carbohydrate metabolism, and glycerophospholipid metabolism. Conclusions: Compared with glimepiride, liraglutide treatment led to greater changes in the circulating metabolome, particularly regarding lipid metabolism involving sphingolipids, including ceramides. Our findings are hypothesis-generating and shed light on the underlying biological mechanisms of the CV benefits observed with GLP-1 RAs in outcome studies. Further studies investigating the role of GLP-1 RAs on ceramides and CV disease including fatty liver disease are warranted. Trial registration: NCT01425580
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Heatmap depicting log2 transformed levels of metabolites at baseline and after treatment [glimepiride + metformin (G) vs. liraglutide + metformin (L)]. Groups were further divided into subjects with myocardial infarction (MI) or without MI (C, control)](https://figures.cochat.ai/paper-figures/f80c87c143c94a1ba75742434dd8b39d/pharmacometabolomic-profiles-in-type-2-diabetic-subjects-treated-with-figure-1.jpg)
![Fig. 2 A Heatmap demonstrating differences in lipids, at baseline, between individuals with (n = 21) or without myocardial infarction (MI) (n = 41). B Selected examples of lipids, i.e., ceramide [Cer(d18:1/24:1)], triacylglycerol [TG(56:3)] and phosphatidylethanolamine [PE(35:5)], showing significant differences at baseline between groups with or without MI, with adjusted p values marked to the boxplots](https://figures.cochat.ai/paper-figures/f68170fbf24e470ab39636e61fadd6cc/pharmacometabolomic-profiles-in-type-2-diabetic-subjects-treated-with-figure-2.jpg)
![Fig. 3 A Heatmap of fold changes between treated groups [glimepiride (G) vs. liraglutide (L)]. B Selected examples of lipids, i.e., phosphatidylcholine [PC(36:4)], phosphatidylethanolamines [PE(18:1/8:2)], lysophosphatidylcoline [LPC(18:2)] and triacylglycerol [TG(18:0/18:1/20:4)], showing significant difference between treated groups [glimepiride (G) vs. liraglutide (L)], with adjusted p values marked to the boxplots](https://figures.cochat.ai/paper-figures/2f6fea6e353e4354933c0261262de0f2/pharmacometabolomic-profiles-in-type-2-diabetic-subjects-treated-with-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, Jendle et al.134 showed that 18 weeks of treatment with liraglutide compared with glimepiride significantly reduced a more significant number of lipid species, including ceramides, PCs, phosphatidylinositol, cholesterol esters, and sphingomyelins.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“In the LEADER (Liraglutide Effect and Action in Diabetes) trial [6] the time-to-event analysis for the composite endpoint, i.”
BackgroundChalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis
Chong, J., Soufan, O., Li, C., Caraus, I., Li, S., Bourque, G., Wishart, D. S., & Xia, J. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky310 · Cited by 3,629
Byrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,042
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 1×
“Several clinical studies with the treatment of GLP-1 RAs shown improved lipid metabolism and amelioration of cardiometabolic risk factors [21].”
BackgroundObesity Phenotypes, Diabetes, and Cardiovascular Diseases
Piché, M.-E., Tchernof, A., & Després, J.-P. (2020) · Circulation Research · doi:10.1161/circresaha.120.316101 · Cited by 1,986
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Wong, R. J., Aguilar, M., Cheung, R., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.11.039 · Cited by 1,819
Cited by
Lipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
Angelidi, A. M., Kokkinos, A. D., Sanoudou, D., Connelly, M. A., Alexandrou, A. P., Mingrone, G., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155346 · Cited by 61
Gao, J., Yang, T., Song, B., Ma, X., Ma, Y., Lin, X., & Wang, H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115395 · Cited by 64
Piccirillo, F., Mastroberardino, S., Nusca, A., Frau, L., Guarino, L., Napoli, N., Ussia, G. P., & Grigioni, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210164 · Cited by 58
Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure
Sforza, A., Vigorelli, V., Rurali, E., Perrucci, G. L., Gambini, E., Arici, M., Metallo, A., Rinaldi, R., Fiorina, P., Barbuti, A., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01486-9 · Cited by 37
Metadata
- Authors
- Jendle, J., Hyötyläinen, T., Orešič, M., & Nyström, T.
- Affiliations
- Örebro University (SE)
- Karolinska Institutet (SE)
- Corresponding author
- Jendle, J.
- Venue
- Cardiovascular Diabetology
- Published
- 2021-12
- Volume
- 20
- Issue
- 1
- Pages
- 237-237
- ISSN
- 1475-2840 (ISSN-L)
- PMC
- PMC8684205
- OpenAlex
- W4200606167
- Cited by
- 27
- References
- 48
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 7 · 2023: 10 · 2022: 4
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 16 d)
- Locations
- Cardiovascular Diabetology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Novo Nordisk
- Örebro University
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- liraglutide, glimepiride, type 2 diabetes, pharmacometabolomics, GLP-1 receptor agonists, plasma lipid metabolism, sphingolipids, ceramide, lysophosphatidylcholine, bile acids, hepatic steatosis, cardiovascular disease, metformin, tryptophan metabolism, glycerophospholipid metabolism, glucose metabolism
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Lipidomics, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Chromatography, High Pressure Liquid, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hypoglycemic Agents, Lipids, Male, Metformin, Middle Aged, Sulfonylurea Compounds, Time Factors, Biomarkers, Treatment Outcome, Spectrometry, Mass, Electrospray Ionization, Incretins, Metabolomics, Metabolome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. https://app.cochat.ai/papers/10.1186/s12933-021-01431-2
- The paper
- Jendle, J., Hyötyläinen, T., Orešič, M., & Nyström, T. (2021). Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-021-01431-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.